StockDuty ← Dashboard Oct 24, 2026 02:55 PM ET
SignalFDA/Bio

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial - Reuters

J&J's prostate cancer drug shrank tumors in an early-stage trial, per Reuters.

J&J's prostate cancer drug shrank tumors in an early-stage trial, per Reuters.
J&J's prostate cancer drug shrank tumors in an early-stage trial, per Reuters. — impact context not separately stored; see What changed.
Sources